Cancer and the Microbiome: How Bacteria Influence Immunotherapy with Dr. Gregory Sonnenberg

CRI LJO STAR Dr. Gregory Sonnenberg discusses the influence of the microbiome in cancer. #CRIwebinar #microbiome https://www.cancerresearch.org/events...

The microbiome—the trillions of skin bacteria, gut bacteria, and other microscopic organisms that inhabit our bodies—has emerged as an exciting area of research in the past few years. Studies suggest it impacts both the development and progression of cancer as well as patient responses to immunotherapy.

In this webinar for patients and caregivers, Gregory Sonnenberg, Ph.D., of Weill Cornell Medicine highlights what we know so far about the human microbiome and how factors such as diet and probiotics influence the health of our gut flora. Microbiome-based treatment strategies are already being explored in the clinic to improve outcomes for cancer patients, and our expert focuses on the biggest challenges and questions that must be addressed.

Dr. Gregory ​Sonnenberg is an associate professor of microbiology and immunology in medicine at the Weill Cornell Medical College in New York City. He also has primary appointments in the Department of Medicine and Gastroenterology Division, the Department of Microbiology and Immunology, and the Jill Robert’s Institute for Research in IBD at Cornell University. Previously, Dr. Sonnenberg completed his Ph.D. and was a postdoctoral researcher at the University of Pennsylvania Perelman School of Medicine. He has also been a recipient of the NIH Director’s Early Independence Award, the Searle Scholar Award, the Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease Award, and has appeared on the Forbes list of rising stars transforming Science and Healthcare. He is also a CRI Lloyd J. Old STAR (2019-2024) and CRI CLIP Investigator (2019-2021).

The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is hosted by our science writer, Arthur Brodsky, Ph.D. The 2020 series is made possible with generous support from Bristol-Myers Squibb and Foundation Medicine.

Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org

Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.